SCHEMBL15937330

SCHEMBL15937330

CC1(C)c2ccccc2N2c3ccccc3C(C)(C)c3cc(-c4ccc(-c5ccc(-c6cc7c8c(c6)C(C)(C)c6cc(-c9ccccc9)ccc6N8c6ccc(-c8ccccc8)cc6C7(C)C)cc5)cc4)cc1c32

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.34
CYP2D6 P10635 2/20 0.34
PDK2 Q15119 2/20 0.34
CYP1A2 P05177 1/20 0.34
HSD17B3 P37058 1/20 0.33
PGR P06401 2/20 0.32
NPSR1 Q6W5P4 2/20 0.32
LMNA P02545 2/20 0.32
HTT P42858 2/20 0.32
ITGB2 P05107 1/20 0.32
ICAM1 P05362 1/20 0.32
ITGAL P20701 1/20 0.32
MAPT P10636 2/20 0.31
RARA P10276 1/20 0.31
RARB P10826 1/20 0.31
RARG P13631 1/20 0.31
KDM4E B2RXH2 1/20 0.31
MEN1 O00255 1/20 0.31
GAA P10253 1/20 0.31
THRB P10828 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15937277 1.00 KMT2A (0.34) KMT2ACYP2D6PDK2CYP1A2HSD17B3
SCHEMBL15937363 1.00 KMT2A (0.34) KMT2ACYP2D6PDK2CYP1A2HSD17B3
SCHEMBL13371089 1.00 KMT2A (0.34) KMT2ACYP2D6PDK2CYP1A2HSD17B3
SCHEMBL15937310 0.97 RARA (0.35) KMT2ACYP2D6PDK2CYP1A2HSD17B3
SCHEMBL15937344 0.97 RARA (0.35) KMT2ACYP2D6PDK2CYP1A2HSD17B3
SCHEMBL13371154 0.97 RARA (0.35) KMT2ACYP2D6PDK2CYP1A2HSD17B3
SCHEMBL15937335 0.97 RARA (0.35) KMT2ACYP2D6PDK2CYP1A2HSD17B3
SCHEMBL15937275 0.95 PGR (0.33) KMT2APDK2HSD17B3PGRHTT
SCHEMBL15937316 0.95 PGR (0.33) KMT2APDK2HSD17B3PGRHTT
SCHEMBL15937360 0.95 PGR (0.33) KMT2APDK2HSD17B3PGRHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160126476-A1 NOVEL COMPOUND, LIGHT EMITTING DEVICE COMPRISING SAME, AND ELECTRONIC DEVICE LMS CO., LTD. (KR) 2016-05-05 US disclosed
US-20160126476-A1 NOVEL COMPOUND, LIGHT EMITTING DEVICE COMPRISING SAME, AND ELECTRONIC DEVICE LMS CO., LTD. (KR) 2016-05-05 US disclosed
WO-2014119895-A1 NOVEL COMPOUND, LIGHT EMITTING DEVICE COMPRISING SAME, AND ELECTRONIC DEVICE 주식회사 엘엠에스 (KR) 2014-08-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160126476-A1 NOVEL COMPOUND, LIGHT EMITTING DEVICE COMPRISING SAME, AND ELECTRONIC DEVICE ELAVL1, SUN2, PER2 KMT2A 2131/4885CYP2D6 723/4885PDK2 2946/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.